ArticleCancers2025
Beyond Carcinoembryonic Antigens: The Role of CA-125 and CA-199 in Predicting Prognosis of Lung Adenocarcinoma.
Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Editorial: Lung Cancer-From Mechanisms of Action and Risk Factors in Disease Onset to Management.Cancers · 2026Article
- Leveraging Acquired EGFR-TKI-Resistant Models to Identify MUC16 as a Therapeutic Vulnerability in Lung Adenocarcinoma.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung adenocarcinoma in Taiwan has unique characteristics, such as a high EGFR mutation rate. While CEAs are a commonly used serum tumor marker (STM), the prognostic value of CA-125, CA-153, and CA-199 remains unclear. This study evaluates their clinical utility in predicting disease progression and prognosis.
methodsA multicenter retrospective study of 1133 patients with lung adenocarcinoma from three hospitals in Taiwan was conducted (2014-2021). Clinical data and STM levels (CEA, CA-125, CA-153, CA-199) were collected. Cox proportional hazards models were used to identify independent predictors of disease-free survival (DFS) and progression-free survival (PFS).
resultsCEA, CA-125, CA-153, and CA-199 levels increased with lung adenocarcinoma stage (
conclusionsCA-125 and CA-199 may be superior to CEAs in predicting poor PFS in stage IV lung adenocarcinoma, especially for EGFR TKI-treated patients. These easily accessible markers could aid prognosis and treatment decisions, although further validation is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.